pyrazines has been researched along with Weight Loss in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 21 (87.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullahi, A; Auger, C; Barayan, D; Jeschke, MG; Knuth, CM; Vinaik, R | 1 |
| Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C | 1 |
| Al-Shurbaji, A; Denison, H; Eriksson, JW; Himmelmann, A; Knutsson, M; Löfgren, L; Mårtensson, G; Nilsson, C; Tornqvist, H | 1 |
| Hardy, E; Jabbour, SA; Parikh, S; Sugg, J | 1 |
| Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Tibaldi, JM | 1 |
| Bethel, LM; Caroline, AL; Hartman, AL; Oury, TD; Powell, DS; Reed, DS | 1 |
| Guthrie, R; Slee, A; Traina, S | 1 |
| Cornell, S | 1 |
| Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A | 1 |
| Byrd, JC; Coombes, KR; Coss, CC; Covey, T; Gardner, HL; Gulrajani, M; Hamdy, A; Harrington, BK; Izumi, R; Johnson, AJ; Kaptein, A; Kisseberth, WC; Krejsa, C; London, CA; Rothbaum, W; Russell, DS; Urie, BK; Van Lith, B; Zhang, X | 1 |
| Meier, JJ; Menge, BA; Schmidt, WE | 1 |
| Berria, R; Davis, KL; Horton, ES; Silberman, C | 1 |
| Unger, J | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 1 |
| Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
| Boddu, ND; Cheskin, LJ; Kahan, S; Kumar, AA; Palamaner Subash Shantha, G; Samson, RJ | 1 |
| Davies, M; Speight, J | 1 |
| Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B | 1 |
| Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL | 1 |
5 review(s) available for pyrazines and Weight Loss
| Article | Year |
|---|---|
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.
Topics: Adult; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2015 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2012 |
10 trial(s) available for pyrazines and Weight Loss
| Article | Year |
|---|---|
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triazoles; Triglycerides; Weight Loss | 2014 |
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Topics: Acetates; Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diarrhea; Dose-Response Relationship, Drug; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Male; Middle Aged; Obesity; Peptide YY; Pyrazines; Treatment Outcome; Weight Loss | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss | 2014 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Kidney Transplantation; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2013 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Topics: Adult; Age Factors; Aged; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Behavior; Humans; Hypoglycemic Agents; Male; Middle Aged; Personal Satisfaction; Pyrazines; Quality of Life; Self Efficacy; Sex Factors; Sexual Behavior; Sitagliptin Phosphate; Thiophenes; Triazoles; Weight Loss | 2014 |
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Anorexia; Antineoplastic Agents; B-Lymphocytes; Benzamides; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Disease-Free Survival; Dogs; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Humans; Lethargy; Lymphoma, Large B-Cell, Diffuse; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Vomiting; Weight Loss | 2016 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss | 2013 |
9 other study(ies) available for pyrazines and Weight Loss
| Article | Year |
|---|---|
Inhibition of Lipolysis With Acipimox Attenuates Postburn White Adipose Tissue Browning and Hepatic Fat Infiltration.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Blotting, Western; Burns; Fatty Acids, Nonesterified; Immunohistochemistry; Lipolysis; Liver; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sterol Esterase; Weight Loss | 2020 |
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever.
Topics: Amides; Animals; Antiviral Agents; Chemoprevention; Female; Fever; Pyrazines; Rats; Rats, Inbred WF; Rift Valley Fever; Survival Analysis; Treatment Outcome; Weight Loss | 2014 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxadiazoles; Proto-Oncogene Proteins c-fos; Pyrazines; Receptors, G-Protein-Coupled; Weight Loss | 2015 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Overweight; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Weight Loss | 2012 |
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss | 2005 |